ATLAS fair value
ATLAS has no fair value for this stock today.
BB Biotech stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · SIX Swiss Exchange · Switzerland
Prices as of Oct 26, 2026 · CHF
ATLAS has no fair value for this stock today.
53%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives BB Biotech a 53% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CHF 47.67 and CHF 51.57; in 9 out of 10, between CHF 44.47 and CHF 55.28. Estimated annual volatility is 22%.
ATLAS does not publish a fair value for BION.SW right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks BION.SW has traded between CHF 40.05 and CHF 57.00. Today it is 13.3% below that high and 23% above its low.
On the business: net margin is 127.3%; it trades at 2.5 times earnings.
Its beta is 0.67: it tends to move less than the market.
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
Want to see everything about BB Biotech?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
53%: close to a coin flip. In half of the simulated outcomes, BION.SW ends the month between CHF 47.67 and CHF 51.57.
BB Biotech's market capitalization is CHF 2.7B. Its price-to-earnings (P/E) ratio is 2.5: you pay CHF 2.51 for each CHF 1.00 of yearly earnings.
ATLAS estimates annual volatility at 22%. In a typical month, half of the outcomes end between CHF 47.67 and CHF 51.57.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy